Open AccessPapillary Dermal Elastolysis Secondary to Combination Nivolumab and Cabiralizumab Therapy: Histiocytes and Dermal Mucin as Clues to the Diagnosis
Author(s) -
Lu Yin,
Maressa C. Criscito,
Evan Stokar,
Despina Siolas,
Adele Haimovic,
Kristen Lo Sicco,
Nooshin K. Brinster
Publication year - 2021
Publication title -
the american journal of dermatopathology/american journal of dermatopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.454
H-Index - 73
eISSN - 1533-0311
pISSN - 0193-1091
DOI - 10.1097/dad.0000000000001915
Subject(s) - dermis , histiocyte , medicine , pathology , papillary dermis , nivolumab , mucin , adenocarcinoma , dermatology , immunotherapy , cancer
Papillary dermal elastolysis has been described in the setting of experimental combination nivolumab and cabiralizumab immunotherapy. We report a third patient with distinctive, generalized atrophic macules that developed after a morbilliform eruption during a clinical trial for treatment of metastatic pancreatic adenocarcinoma. Histopathological findings demonstrated diminished elastic fibers in the papillary dermis, associated with a histiocyte-rich infiltrate and increased dermal mucin, features that should clue the dermatopathologist to this condition.